Wed, Jun. 22, 4:14 PM
Fri, Jun. 10, 7:28 AM
- Sarepta Therapeutics (NASDAQ:SRPT) upgraded to Outperform from Neutral by Wedbush. Price target raised to $36 (71% upside) from $14.
- EnteroMedics (NASDAQ:ETRM) downgraded to Neutral from Buy by Roth Capital Partners. Price target is $0.50 (11% upside).
- Relypsa (NASDAQ:RLYP) downgraded to Underweight from Equal Weight by Morgan Stanley. Price target maintained at $9 (52% downside risk).
- Mirati Therapeutics (NASDAQ:MRTX) downgraded to Hold from Buy by Jefferies. Price target lowered to $17 (77% upside) from $27.
- AbbVie (NYSE:ABBV) downgraded to Market Perform from Outperform by Cowen & Company. Price target lowered to $70 (15% upside) from $77. Downgraded to Equal Weight from Overweight by Morgan Stanley. Price target lowered to $65 (7% upside) from $73.
- WebMD (NASDAQ:WBMD) downgraded to Market Perform from Outperform by William Blair.
Mon, Jun. 6, 12:48 PM
Mon, Jun. 6, 11:10 AM
- Thinly traded micro cap Mirati Therapeutics (MRTX -40.1%) plummets in early trading on a 6x surge in volume in response to its update on its clinical trials. The company reported results from a Phase 1b study evaluating lead product glesatinib, a tyrosine kinase inhibitor that selectively targets certain genetic profiles of lung cancer patients called MET and Axl, in 22 subjects with non-small cell lung cancer (NSCLC).
- 11 of the 22 participants had genetic driver alterations similar to the selection criteria for the company's ongoing Phase 2 study. Tumor regression was observed in 10 of the 11 (90.9%), but only three (27.3%) were partial responders pre RECIST criteria.
- Side effects appeared to be a problem, however. Nine of the 11 subjects (81.8%) experienced dose reductions and or dose interruptions. Four of the nine experienced one reduction, two had two reductions and three had multiple reductions while on study. Eight of the subjects are no longer on trial: five discontinued due to disease progression, two related to adverse events and one withdrew consent. The dose reductions were due primarily to episodes of diarrhea. According to the company, the likely culprit was the presence of a castor oil-like ingredient in glesatinib's formulation called miglyol.
- To address the problem, a new spray-dried dispersion formulation of glesatinib is being implemented in the Phase 2 study. One partial responder who moved to the new formulation has shown an improved response and remains on study but at a dose of 500 mg twice daily, lower that the established dose of 750 mg twice daily. According to clinicaltrials.gov, the estimated final data collection date for the primary endpoint is July 2017. The estimated study completion date is July 2018.
Mon, Jun. 6, 11:01 AM
Mon, Jun. 6, 9:15 AM
Fri, May 6, 12:45 PM
Thu, May 5, 5:56 PM
Wed, Mar. 9, 4:26 PM
Dec. 21, 2015, 12:17 PM
- Mirati Therapeutics (MRTX -1%) initiates a Phase 2 clinical trial assessing lead product candidate, MGCD265 (glesatinib) in non-small cell lung cancer (NSCLC) patients with MET gene mutations.
- The open-label, single-agent, international, multicenter study will enroll MET-positive NSCLC patients who failed to respond to a platinum-based chemo regimen. The primary endpoint is objective response rate. Secondary endpoints include progression-free survival. According to clinicaltrials.gov, the estimated final data collection date for the primary endpoint is July 2017. The estimated study completion date is July 2018.
- MGCD265 inhibits an enzyme called tyrosine kinase, selectively targeting the MET and Axl genes, whose mutations are associated with tumor growth and disease progression.
Nov. 6, 2015, 8:20 AM
- Mirati Therapeutics (NASDAQ:MRTX): Q3 EPS of -$1.11 misses by $0.23.
Sep. 14, 2015, 4:07 PM
- Mirati Therapeutics (NASDAQ:MRTX) commences an $80M offering of common shares. Underwriters over-allotment will be an additional 15% of the number of shares offered. Price, volume and terms have yet to be announced.
Sep. 11, 2015, 12:44 PM
Aug. 6, 2015, 5:17 PM
- Mirati Therapeutics (NASDAQ:MRTX): Q2 EPS of -$0.95 misses by $0.21.
Jun. 2, 2015, 4:25 PM| Jun. 2, 2015, 4:25 PM | 1 Comment
Jun. 1, 2015, 11:43 AM
- Thinly traded Mirati Therapeutics (MRTX -17.2%) slumps on a 7x surge in volume in response to the presentation of an abstract (#2589) at ASCO on a Phase 1 trial of its tyrosine kinase inhibitor, MGCD265, in heavily pretreated patients with non-small cell lung cancer (NSCLC) with MET gene mutations.
- According to investigators, MGCD265 showed anti-tumor activity and clinical benefit (improvements in pain and shortness of breath) in the first three patients treated, but none met RECIST criteria for responses, which is the metric used in clinical trials.
- RECIST (Response Evaluation Criteria in Solid Tumors) is a standardized method to measure the change in tumor burden.
Mirati Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing a pipeline of targeted oncology products. It also focuses on its development programs on drugs intended to treat specific subsets of cancer patients with unmet needs. The company's pipeline... More
Industry: Drug Related Products
Country: United States
Other News & PR